CI
LKFT

Cavalier Investments’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Cavalier Investments’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,400
Closed -$214K – 113
2015
Q4 		$214K Buy
+3,400
New +$174K 0.13% 106

Other funds holding LKFT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Cavalier Investments's LKFT Position: Q1 2016 in Review

Cavalier Investments sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q1 2016, closing a stake of 3,400 shares — an estimated $214K sold.

Cavalier Investments first reported a position in LKFT in Q4 2015 and held it in 1 quarter. The position peaked at $214K in Q4 2015. 32 funds tracked by Wall St. Rank hold LKFT as of Q1 2016.

  • Cavalier Investments reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q1 2016 after selling out during the quarter.
  • Cavalier Investments sold 3,400 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2016, an estimated $214K.
  • Cavalier Investments first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2015 and held it in 1 quarter.
  • Cavalier Investments's Lakefront Biotherapeutics American Depositary Shares position peaked at $214K in Q4 2015.
  • 32 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2016.

Based on Cavalier Investments's 13F filing for Q1 2016, filed 13 May 2016.